Management of Severe Hypertension with Dizziness using Nitroglycerin

Introduction to Nitroglycerin Use

• The American College of Cardiology and Circulation journal recommend Nitroglycerin (NTG) for the treatment of severe hypertension with dizziness, particularly when associated with acute coronary syndromes, heart failure, or pulmonary congestion, with cautious use to avoid excessive blood pressure reduction 1, 2, 3

Mechanism of Action and Effects

• NTG acts as an endothelium-independent vasodilator with both peripheral and coronary vascular effects, primarily through dilation of venous capacitance vessels, decreasing preload and reducing ventricular wall tension, and coronary artery dilation, improving myocardial oxygen delivery 4, 5

Administration Guidelines

• The American College of Cardiology recommends beginning with sublingual NTG 0.3-0.6 mg (up to 1.5 mg) for immediate effect, with an onset of 1-7 minutes 6, 7
• If inadequate response, consider intravenous administration, starting at 10 mcg/min via continuous infusion, increasing by 10 mcg/min every 3-5 minutes until symptom relief or blood pressure response 4, 5, 6

Cautions and Contraindications

• The American Heart Association and Circulation journal advise against titrating systolic BP below 110 mmHg in previously normotensive patients, and reducing BP more than 25% below baseline mean arterial pressure if hypertension was present 2, 6
• Absolute contraindications include use of phosphodiesterase inhibitors, initial systolic BP less than 90 mmHg, marked bradycardia or tachycardia, and right ventricular infarction 1, 6

Monitoring and Side Effects

• Common side effects include headache and hypotension, with tolerance developing within 7-8 hours of continuous infusion 6, 7
• Monitor for blood pressure response, symptoms of ischemia, signs of excessive hypotension, and heart rate changes 2, 4, 6

Alternative Approaches

• If NTG is contraindicated or ineffective, consider beta-blockers, calcium channel blockers, or ACE inhibitors, with a transition to oral agents for long-term management 1, 2, 9